ImmuneResearch Phase

Alpha-MSH

Subcutaneous injection, Intravenous

Overview

Alpha-melanocyte-stimulating hormone (alpha-MSH) is a 13-amino-acid peptide derived from proopiomelanocortin (POMC). It acts via melanocortin receptors to exert potent anti-inflammatory and immunomodulatory effects, including suppression of proinflammatory cytokines and inhibition of nuclear factor kappa B (NF-kB).

Mechanism of Action

Therapeutic interest spans inflammatory and autoimmune disorders..

Research Summary & Key Findings

Preclinical models have demonstrated efficacy in reducing inflammation in conditions such as colitis, arthritis, and uveitis. Clinical translation has been limited, with synthetic analogs under exploration, but no large-scale trials or approvals for alpha-MSH itself have been reported.

Clinical Status

Research Phase

Alpha-MSH is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Subcutaneous injectionIntravenous

Related Peptides in Immune

Find a Provider

Find a verified provider who offers Alpha-MSH therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Alpha-MSH.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.